Approved for VARUBI ® is indicated in combination with other antiemetic agents in adults for the prevention of delayed nausea and vomiting associated with initial and repeat courses of emetogenic cancer chemotherapy, including, but not limited to, highly emetogenic chemotherapy.. Rolapitant is a selective and competitive antagonist of human substance P/NK1 receptors. Rolapitant does not have…
Loading full data from Know Your Drugs Institute…